Download PDF
pferde spiegel 2014; 17(2): 75-83
DOI: 10.1055/s-0034-1368439
cve
Enke Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG Stuttgart · New York

Das Sarkoid als häufigster Hauttumor bei Pferden und Pferdeartigen

Edmund K. Hainisch
,
Sabine Brandt
Further Information

Publication History

Publication Date:
16 June 2014 (online)

    Permissions and Reprints All articles of this category

Das Sarkoid ist mit einer Prävalenz von 1–12 % der häufigste Hauttumor bei Pferdeartigen; also Pferden, Eseln, Maultieren, Mauleseln und Zebras. Sowohl bei seiner Induktion als auch bei der Progression spielen Traumen eine entscheidende Rolle. Ist die korrekte Diagnose gestellt, sollte bei allen Sarkoiden eine wirksame, individuell angepasste Therapie durchgeführt werden.

 

  • Literatur

  • 1 Ashrafi GH, Piuko K, Burden F, Yuan Z, Gault EA, Müller M, Trawford A, Reid SW, Nasir L, Campo MS. Vaccination of sarcoid-bearing donkeys with chimeric virus-like particles of bovine papillomavirus type 1. J Gen Virol 2008; 89 (1) 148-157
    CrossrefGoogle Scholar
  • 2 Bergvall KE. Sarcoids. Vet Clin North Am Equine Pract 2013; 29 (3) 657-671
    CrossrefGoogle Scholar
  • 3 Bogaert L, Martens A, Van Poucke M, Ducatelle R, De Cock H, Dewulf J, De Baere C, Peelman L, Gasthuys F. High prevalence of bovine papillomaviral DNA in the normal skin of equine sarcoid-affected and healthy horses. Vet Microbiol 2008; 129(1–2): 58-68
    CrossrefGoogle Scholar
  • 4 Broström H, Fahlbrink E, Dubath ML, Lazary S. Association between equine leucocyte antigens (ELA) and equine sarcoid tumors in the population of Swedish halfbreds and some of their families. Vet Immunol Immunopathol 1988; 19(3–4): 215-223
    CrossrefGoogle Scholar
  • 5 Campo MS. Papillomavirus Research. Caister Academic Press; 2006
    Google Scholar
  • 6 Carr EA, Théon AP, Madewell BR, Griffey SM, Hitchcock ME. Bovine papillomavirus DNA in neoplastic and nonneoplastic tissues obtained from horses with and without sarcoids in the western United States. Am J Vet Res 2001; 62 (5) 741-744
    CrossrefGoogle Scholar
  • 7 Chambers G, Ellsmore VA, OʼBrien PM, Reid SW, Love S, Campo MS, Nasir L. Association of bovine papillomavirus with the equine sarcoid. J Gen Virol 2003; 84 (5) 1055-1062
    CrossrefGoogle Scholar
  • 8 Espy BM. How to treat equine sarcoids by autologous implantation. AAEP Proceedings 2008; 54: 68-73
    Google Scholar
  • 9 Hainisch EK, Abel H, Shafti-Keramat S, Kirnbauer R, Brandt S. BPV-1 L1 VLP Vaccination protects horses from experimental BPV-1 Infection. 28th International Papillomavirus Conference; Nov 30 – Dec 6, 2012; San Juan, Puerto Rico.
    Google Scholar
  • 10 Hainisch EK, Brandt S, Shafti-Keramat S, Van den Hoven R, Kirnbauer R. Safety and immunogenicity of BPV-1 L1 virus-like particles in a dose-escalation vaccination trial in horses. Equine Vet J 2012; 44 (1) 107-111
    CrossrefGoogle Scholar
  • 11 Hallamaa RE, Saario E, Tallberg T. Macroscopical and histopathological changes in regressing primary and recurrent equine sarcoids during active specific bio-immunotherapy. In vivo (Athens, Greece) 2005; 19 (4) 761-767
    Google Scholar
  • 12 Hewes CA, Sullins KE. Use of cisplatin-containing biodegradable beads for treatment of cutaneous neoplasia in equidae: 59 cases (2000–2004). J Am Vet Med Assoc 2006; 229 (10) 1617-1622
    CrossrefGoogle Scholar
  • 13 Kemp-Symonds JG, Nixon JVM. Carbon Dioxide Laser Surgery as a Treatment for Equine Sarcoid: Outcome and Complications in 24 Patients. Proceedings of the BEVA Congress, 2008: 251.
    Google Scholar
  • 14 Kirnbauer R. Papillomavirus-like particles for serology and vaccine development. Intervirology 1996; 39(1–2): 54-61
    Google Scholar
  • 15 Klein WR, Bras GE, Misdorp W, Steerenberg PA, de Jong WH, Tiesjema RH, Kersjes AW, Ruitenberg EJ. Equine sarcoid: BCG immunotherapy compared to cryosurgery in a prospective randomised clinical trial. Cancer Immunol Immunother 1986; 21 (2) 133-140
    CrossrefGoogle Scholar
  • 16 Knottenbelt DC, Kelly DF. The diagnosis and treatment of periorbital sarcoid in the horse: 445 cases from 1974 to 1999. Vet ophthalmol 2000; 3(2–3): 169-191
    CrossrefGoogle Scholar
  • 17 Mattil-Fritz S, Scharner D, Piuko K, Thönes N, Gissmann L, Müller H, Müller M. Immunotherapy of equine sarcoid: dose-escalation trial for the use of chimeric papillomavirus-like particles. G Gen Virol 2008; 89(Pt 1): 138-147
    Google Scholar
  • 18 Nasir L, Brandt S. Papillomavirus associated diseases of the horse. Vet Microbiol 2013; 167(1–2): 159-167
    CrossrefGoogle Scholar
  • 19 Nasir L, Campo MS. Bovine papillomaviruses: their role in the aetiology of cutaneous tumours of bovids and equids. Vet Dermatol 2008; 19 (5) 243-254
    CrossrefGoogle Scholar
  • 20 Nasir L, Reid SW. Bovine papillomaviruses and equine sarcoids. In: M.S. CAMPO, ed. Papillomavirus Research. From natural history to vaccines and beyond. Norfolk: Caister Academic Press; 2006: 389-397
    CrossrefGoogle Scholar
  • 21 Nogueira SA, Torres SM, Malone ED, Diaz SF, Jessen C, Gilbert S. Efficacy of imiquimod 5 % cream in the treatment of equine sarcoids: A pilot study. Vet Dermatol 2006; 17 (4) 259-265
    CrossrefGoogle Scholar
  • 22 Pascoe RR, Knottenbelt DC. Manual of Equine Dermatology. Philadelphia: Saunders; 1999
    Google Scholar
  • 23 Pilsworth RC, Knottenbelt DC. Equine Sarcoid. Eq Vet Educ 2007; 19: 260-262
    CrossrefGoogle Scholar
  • 24 Rooney JR, Robertson JL. Equine Pathology. Ames: Iowa State University Press; 1996
    Google Scholar
  • 25 Scott DW, Miller WHJ. Equine Dermatology. St. Louis: Saunders; 2003
    Google Scholar
  • 26 Stadler S, Kainzbauer C, Haralambus R, Brehm W, Hainisch E, Brandt S. Successful treatment of equine sarcoids by topical aciclovir application. Vet Rec 2011; 168 (7) 187
    CrossrefGoogle Scholar
  • 27 Théon AP, Wilson WD, Magdesian KG, Pusterla N, Snyder JR, Galuppo LD. Long-term outcome associated with intratumoral chemotherapy with cisplatin for cutaneous tumors in equidae: 573 cases (1995–2004). J Am Vet Med Assoc 2007; 230 (10) 1506-1513
    CrossrefGoogle Scholar
  • 28 Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6 (5) 271-278
    Google Scholar